Clinical trials: Advanced Solid Malignancy
Advanced Malignancy, Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT01723020
- Testing
- AMG 232
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Kartos Therapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00004059
- Testing
- 7-hydroxystaurosporine, fluorouracil
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT07288359
- Testing
- GVV858, Fulvestrant, Letrozole
- Where
- 16 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Tumors
A Study of ABT-414 in Subjects With Solid Tumors
A study of ABT-414 in subjects with solid tumors.
- Trial name
- NCT01741727
- Testing
- ABT-414
- Where
- 6 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HRD Cancer, SCLC
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Background: Small cell lung cancer and PARP inhibitor resistant tumors are aggressive cancers. Current treatments for people with these tumors yield little benefit. Researchers want to see if a combination of drugs can help.
- Conditions
- HRD Cancer, SCLC, Advanced Solid Tumors
- Trial name
- NCT04826341
- Testing
- Berzosertib, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab.
- Trial name
- NCT02722954
- Testing
- Demcizumab, Pembrolizumab
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 29 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination…
- Trial name
- NCT00002505
- Testing
- filgrastim, recombinant interferon gamma, tumor cell lysate vaccine therapy
- Where
- 4 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumors, TGCT
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose…
- Trial name
- NCT05277454
- Testing
- HMPL-653
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hutchison Medipharma Limited
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Metastatic or Locally Advanced Solid Tumors
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.
- Trial name
- NCT01285466
- Testing
- BEZ235 + paclitaxel, BKM120 + paclitaxel, BEZ235 + paclitaxel + trastuzumab
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 110 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Tumors
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there.
- Trial name
- NCT00129337
- Testing
- Bavituximab
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Peregrine Pharmaceuticals
Advanced or Metastatic Solid Malignancy
Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities
Single center, non-randomized, interventional pilot study with feasibility analysis after enrollment of 20 patients. Adult patients with advanced solid tumors, for whom standard palliative treatment with targeted agents as…
- Trial name
- NCT01758575
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Unresectable or Metastatic Solid Tumors
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of…
- Trial name
- NCT03589651
- Testing
- Retifanlimab, Epacadostat, INCB050465
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with colorectal or gastroesophageal cancer that has spread to nearby…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04511039
- Testing
- Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.